Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic
Abstract
:1. Introduction
2. Materials and Methods
- i.
- Marketing authorization (granted by ARCSA);
- ii.
- Advertised indication (the veracity of information on the indication of use, associated risks in special populations, recommendations for use in healthy or chronically ill people);
- iii.
- Use of logos, names of health professionals, offers and prizes.
Statistical Analysis
3. Results
4. Discussion
4.1. Strengths and Limitations of the Study
4.2. Public Health Implications
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
- A
- Digestive system and metabolism
- B
- Blood and hematopoietic organs
- C
- Cardiovascular system
- D
- Dermatologic drugs
- G
- Genitourinary system and sexual hormones
- H
- Systemic hormonal compounds, excluding sexual hormones
- J
- Anti-infective agents in general (for systemic use)
- L
- Anticancer agents and immunomodulators
- M
- Musculoskeletal system
- N
- Nervous system
- P
- Antiparasitic agents and bugs repellants
- R
- Respiratory system
- S
- Sense organs agents
- V
- Various
Item | Yes | No |
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
|
References
- Centro Internacional de Televisión Abierta. Rating Ecuador. Available online: https://www.centrotv.org/es/ratings/ratings-ecuador.html (accessed on 10 August 2022).
- Segura, M.S. Con alerta pero sin pánico. El rol de los medios durante la pandemia. Rev. Fac. Cienc. Méd. Córdoba 2020, 77, 55–58. [Google Scholar]
- Zarocostas, J. How to fight an infodemic. Lancet 2020, 395, 676. [Google Scholar] [CrossRef]
- Guo, J.; Huang, Z.; Lin, L.; Lv, J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infe. J. Am. Heart Assoc. 2020, 9, e016219. [Google Scholar] [CrossRef] [PubMed]
- Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C. The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020, 43, 699–709. [Google Scholar] [CrossRef]
- Casero-Ripollés, A. Impact of COVID-19 on the media system. Communicative and democratic consequences of news consumption during the outbreak. Prof. Inf. 2020, 29, e290223. [Google Scholar] [CrossRef]
- Chavero, P.; Oller Alonso, M. La Comunicación en el Ecuador, ¿derecho o Servicio Público? Rev. Cult. Jurídicas 2014, 1, 164–197. Available online: https://www.researchgate.net/publication/280530772 (accessed on 10 August 2022).
- Fundació Consell de la Informació de Catalunya. Periodistas que Hacen Publicidad: Un Conflicto de Interés; Fundació Consell de la Informació de Catalunya: Barcelona, Spain, 2011; Available online: www.periodistes.org/fcic (accessed on 10 August 2022).
- Organización Panamericana de la Salud. Criterios Éticos para la Promoción, Propaganda y Publicidad de Medicamentos; Documento Técnico N 12; Organización Panamericana de la Salud: Washington, DC, USA, 2013; pp. 1–4. [Google Scholar]
- Organización Mundial de la Salud, Acción Internacional por la Salud. Comprender la Promoción Farmacéutica y Responder a Ella, 1st ed.; Organización Mundial de la Salud: Washington, DC, USA, 2015. [Google Scholar]
- Congreso Nacional de la República del Ecuador. Ley Orgánica de Defensa al Consumidor; Ley No. 2000-21 Ecuador: Ley Orgánica; Congreso Nacional de la República del Ecuador: Quito, Ecuador, 2006. [Google Scholar]
- Vacca, C.; Vargas, C.; Cañás, M.; Reveiz, L.; de Citar, F. Publicidad y promoción de medicamentos: regulaciones y grado de acatamiento en cinco países de América Latina. Rev. Panam. Salud Pub. 2011, 29, 76–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Faerber, A.E.; Kreling, D.H. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. J. Gen. Intern. Med. 2014, 29, 110–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ministerio de Salud Pública del Ecuador. Reglamento para la Publicidad y Promoción de Medicamentos en General, Productos Naturales, Procesados de uso Medicinal, Medicamentos Homeopáticos y Dispositivos Médicos; Registro Oficial, ACUERDO No. 00000179; Control Sanitario: Quito, Ecuador, 2011; pp. 1–5. Available online: www.fielweb.com (accessed on 10 August 2022).
- Organización Mundial de la Salud, Red Panamericana de Armonización de la Reglamentación Farmacéutica. Criterios Éticos Para la Promoción, Propaganda y Publicidad de Medicamentos; Documento Técnico N°12; Organización Mundial de la Salud: Washington, DC, USA, 2013; pp. 1–16. [Google Scholar]
- Congreso Nacional de la República del Ecuador. Ley Orgánica de Salud del Ecuador; Ley 67 Ecuador: Registro Oficial Suplemento 423; Congreso Nacional de la República del Ecuador: Quito, Ecuador, 2006; pp. 1–7. Available online: www.lexis.com.ec (accessed on 10 August 2022).
- Ullod, A.M. Zapping y Publicidad. Quest. Public. 1994, 3, 51–57. Available online: https://ddd.uab.cat/pub/quepub/quepub_a1994n3/quepub_a1994n3p51.pdf (accessed on 10 August 2022). [CrossRef]
- ARCSA Agencia de Control, Regulación, Vigilancia de Medicamentos, Alimentos y Cosméticos. Normativa Sanitaria para el Control de los Suplementos Alimenticios; ARCSA Agencia de Control, Regulación, Vigilancia de Medicamentos, Alimentos y Cosméticos: Quito, Ecuador, 2017; pp. 1–20. [Google Scholar]
- ARCSA. Agencia de Regulación Control y Vigilancia Sanitaria de Medicamentos en el Ecuador. Base de Datos de Alimentos. 2017. Quito, Ecuador. Available online: http://www.controlsanitario.gob.ec/base-de-datos/Alimentos (accessed on 10 August 2022).
- ARCSA. Agencia de Regulación Control y Vigilancia Sanitaria de Medicamentos en el Ecuador. Base de Datos de Medicamentos con Registro Sanitario en Ecuador. Quito, Ecuador. 2017. Available online: http://www.controlsanitario.gob.ec/base-de-datos/Medicamentos (accessed on 10 August 2022).
- Hernández Cruz, A.N. El Rol de los Medios de Comunicación en la Pandemia del COVID-19 a Nivel Mundial. In Reflexiones Desconfinadas para la era posCOVID 19. AntropiQa 2.0, 1st ed.; Vasquez, A., Cambero, S., Eds.; Dialnet: Badajoz, Spain, 2020; pp. 161–178. Available online: https://dialnet.unirioja.es/servlet/libro?codigo=768210 (accessed on 28 October 2020).
- García-castrillón, C.O.; Verschuur, F.; Regulación, L.A.P. La problemática regulación comunitaria de los complementos alimenticios. Trib. Economia. 2007, 836, 163–184. [Google Scholar]
- Ester, S.; García, R. Connotation and Persuasion in the Advertising Image. 2008, Volume 24. Available online: http://hdl.handle.net/10481/6958 (accessed on 10 August 2022).
- Gilbody, S.; Wilson, P.; Watt, I. Benefits and harms of direct to consumer advertising: A systematic review. Qual. Saf. Health Care 2005, 14, 246–250. [Google Scholar] [CrossRef]
- Wilkinson, R.M.M. Social determinants of health. In The Solid Facts; WHO: Copenhagen, Denmark, 2003. [Google Scholar]
- Schwartz, L.M.; Woloshin, S. Medical Marketing in the United States, 1997–2016. JAMA-J. Am. Med. Assoc. 2019, 321, 80–96. [Google Scholar] [CrossRef] [PubMed]
- Mena, M.; Maldonado, X. A Reflection on the Medicalisation of Life: Misleading Advertising. International Society to Improve the Use of Medicines. pp. 7–8. Available online: https://www.isium.org/wp-content/uploads/ISIUM_Newsletter_202103.pdf (accessed on 11 May 2021).
- Parker, L.; Williams, J.; Bero, L. Ethical drug marketing criteria for the 21st century. BMJ 2018, 361, k1809. [Google Scholar] [CrossRef]
- Parekh, N.; Shrank, W.H. Dangers and Opportunities of Direct-to-Consumer Advertising. J. Gen. Intern. Med. 2018, 33, 586–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Robbins, R. Drug Makers Now Spend $5 Billion on a Year on Advertising. Here’s What that Buys. 2016. Available online: https://www.statnews.com/2016/03/09/drug-industry-advertising/ (accessed on 20 July 2022).
- Klara, K.; Kim, J.; Ross, J.S. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. J. Gen. Intern. Med. 2018, 33, 651–658. [Google Scholar] [CrossRef] [Green Version]
- Kiguba, R.; Olsson, S.; Waitt, C. Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. Br. J. Clin. Pharmacol. 2022, 1–19. [Google Scholar] [CrossRef] [PubMed]
General Characteristics | Marketing Authorization of the Products | |
---|---|---|
No–n (%) | Yes–n (%) | |
Private media (n = 425) | 95 (22.3) | 330 (77.6) |
Public media (n = 242) | 54 (22.3) | 188 (77.6) |
Local broadcasts (n = 65) | 29 (44.6) | 36 (55.3) |
National broadcasts (n = 602) | 120 (19.9) | 482 (80) |
Spots in general programming (n = 257) | 90 (35.1) | 167 (64.9) |
Spots in newscasts (n = 410) | 59 (14.3) | 351 (85.6) |
Advertised Health Indication | Total n = 677 * | Newscasts n = 420 | General Programming n = 257 | p-Value ** |
---|---|---|---|---|
Colitis, diarrhea, constipation, heartburn | 119 (17.8) | 66 (9.8) | 53 (8.0) | 0.14 |
Immune system boosters | 108 (16.2) | 86 (13.0) | 22 (3.2) | <0.001 |
Sexual complain/improvement | 95 (14.4) | 94 (22.9) | 1 (0.4) | <0.001 |
Acne or baldness | 74 (11.0) | 43 (6.4) | 31 (4.6) | 0.52 |
Respiratory problems (flu, allergy, etc.) | 68 (10.2) | 12 (1.8) | 56 (8.4) | <0.001 |
Antifungals (topical) | 55 (8.2) | 14 (2.1) | 41 (6.1) | <0.001 |
Pain relieves | 47 (7.0) | 23 (3.4) | 24 (3.6) | 0.09 |
Energy and attention improvement | 46 (6.9) | 36 (5.4) | 10 (1.5) | 0.02 |
Others | 65 (9.7) | 46 (6.9) | 19 (2.8) | 0.13 |
Evaluation Parameters | General Programming (n = 863) * | Newscasts (n = 1480) |
---|---|---|
Uses images, names of health professionals, scientific associations, and regulatory authorities to promote the product | 42 (4.9) | 51 (3.4) |
Advertises curative properties in chronic illnesses not proven by scientific evidence | 73 (8.5) | 146 (9.9) |
Suggests the use of the product in healthy people | 166 (19.2) | 297 (20.1) |
Induces in any way the use of the product in children or during pregnancy or lactation, or omits restrictions on this vulnerable group | 177 (20.5) | 318 (21.5) |
The advertised indications lack scientific support | 197 (22.8) | 323 (21.8) |
Induces indiscriminate, permanent, and unnecessary use of the product | 208 (24.1) | 345 (23.3) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mena, M.B.; Sisa, I.; Teran, E. Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic. Diseases 2022, 10, 91. https://doi.org/10.3390/diseases10040091
Mena MB, Sisa I, Teran E. Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic. Diseases. 2022; 10(4):91. https://doi.org/10.3390/diseases10040091
Chicago/Turabian StyleMena, María Belen, Ivan Sisa, and Enrique Teran. 2022. "Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic" Diseases 10, no. 4: 91. https://doi.org/10.3390/diseases10040091
APA StyleMena, M. B., Sisa, I., & Teran, E. (2022). Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic. Diseases, 10(4), 91. https://doi.org/10.3390/diseases10040091